63 research outputs found
Transcriptomic effects of Tet-on and mifepristone-inducible systems in mouse liver
Control of transgene expression from long-term expression vectors can be achieved with inducible and regulated promoters. The two most commonly used inducible systems employ doxycycline or mifepristone as the drug activating a silent trans-activator, which is expressed from a constitutive promoter. We evaluated the alterations provoked by constitutive expression in the liver of rtTA2(S)-M2 (rtTA2; second-generation reverse tetracycline-controlled trans-activator) and GLp65, which are the trans-activators of the doxycyline- and mifepristone-inducible systems, respectively. To this end we performed transcriptomic analysis of mice expressing these trans-activators in the liver over 1 month. rtTA2 expression induced alterations in a few genes (69 gene probesets; false discovery rate [FDR], approximately 0.05), whereas GLp65 caused more numerous changes (1059 gene probe-sets, an FDR of approximately 0.05). However, only 20 and 53 of the genes from the rtTA2 and GLp65 groups, respectively, showed changes (R-fold >or= 3). Functional assignments indicate that alterations were mild and of little general significance. Few additional transcriptomic changes were observed when expressing trans-activators in the presence of inducer drugs; most were due to the drugs themselves. These results and the absence of toxicity observed in treated animals indicate that the two inducible systems are well tolerated and have little impact on the liver transcriptome profile. The milder alterations found with the use of rtTA2 suggest that this system is possibly safer for gene therapy application
Transcriptomic effects of Tet-on and mifepristone-inducible systems in mouse liver
Control of transgene expression from long-term expression vectors can be achieved with inducible and regulated promoters. The two most commonly used inducible systems employ doxycycline or mifepristone as the drug activating a silent trans-activator, which is expressed from a constitutive promoter. We evaluated the alterations provoked by constitutive expression in the liver of rtTA2(S)-M2 (rtTA2; second-generation reverse tetracycline-controlled trans-activator) and GLp65, which are the trans-activators of the doxycyline- and mifepristone-inducible systems, respectively. To this end we performed transcriptomic analysis of mice expressing these trans-activators in the liver over 1 month. rtTA2 expression induced alterations in a few genes (69 gene probesets; false discovery rate [FDR], approximately 0.05), whereas GLp65 caused more numerous changes (1059 gene probe-sets, an FDR of approximately 0.05). However, only 20 and 53 of the genes from the rtTA2 and GLp65 groups, respectively, showed changes (R-fold >or= 3). Functional assignments indicate that alterations were mild and of little general significance. Few additional transcriptomic changes were observed when expressing trans-activators in the presence of inducer drugs; most were due to the drugs themselves. These results and the absence of toxicity observed in treated animals indicate that the two inducible systems are well tolerated and have little impact on the liver transcriptome profile. The milder alterations found with the use of rtTA2 suggest that this system is possibly safer for gene therapy application
Deciphering Master Gene Regulators and Associated Networks of Human Mesenchymal Stromal Cells.
Mesenchymal Stromal Cells (MSC) are multipotent cells characterized by self-renewal, multilineage differentiation, and immunomodulatory properties. To obtain a gene regulatory profile of human MSCs, we generated a compendium of more than two hundred cell samples with genome-wide expression data, including a homogeneous set of 93 samples of five related primary cell types: bone marrow mesenchymal stem cells (BM-MSC), hematopoietic stem cells (HSC), lymphocytes (LYM), fibroblasts (FIB), and osteoblasts (OSTB). All these samples were integrated to generate a regulatory gene network using the algorithm ARACNe (Algorithm for the Reconstruction of Accurate Cellular Networks; based on mutual information), that finds regulons (groups of target genes regulated by transcription factors) and regulators (i.e., transcription factors, TFs). Furtherly, the algorithm VIPER (Algorithm for Virtual Inference of Protein-activity by Enriched Regulon analysis) was used to inference protein activity and to identify the most significant TF regulators, which control the expression profile of the studied cells. Applying these algorithms, a footprint of candidate master regulators of BM-MSCs was defined, including the genes EPAS1, NFE2L1, SNAI2, STAB2, TEAD1, and TULP3, that presented consistent upregulation and hypomethylation in BM-MSCs. These TFs regulate the activation of the genes in the bone marrow MSC lineage and are involved in development, morphogenesis, cell differentiation, regulation of cell adhesion, and cell structure
Profiling of chemonaive osteosarcoma and paired-normal cells identifies EBF2 as a mediator of osteoprotegerin inhibition to tumor necrosis factor–related apoptosis-inducing ligand–induced apoptosis
Osteosarcoma is the most prevalent bone tumor in children and
adolescents. At present, the mechanisms of initiation, maintenance, and
metastasis are poorly understood. The purpose of this study was to identify
relevant molecular targets in the pathogenesis of osteosarcoma. EXPERIMENTAL
DESIGN: Tumor chemonaive osteoblastic populations and paired control normal
osteoblasts were isolated and characterized phenotypically from seven
osteosarcoma patients. Global transcriptomic profiling was analyzed by robust
microarray analysis. Candidate genes were confirmed by real-time PCR and
organized in molecular pathways. EBF2 and osteoprotegerin (OPG) levels were
determined by real-time PCR and OPG protein levels were assessed by ELISA.
Immunohistochemical analysis was done in a panel of 46 osteosarcoma samples.
Silencing of EBF2 was achieved by lentiviral transduction of short hairpin RNA.
Apoptosis was determined by caspase-3/7 activity. RESULTS: A robust clustered
transcriptomic signature was obtained in osteosarcoma. Transcription factor EBF2,
a known functional bone regulator, was among the most significantly overexpressed
genes. Immunohistochemical analysis showed that osteosarcoma is expressed in
approximately 70% of tumors analyzed. Because EBF2 was shown previously to act as
a transcriptional activator of OPG, elevated levels of EBF2 were associated with
high OPG protein levels in osteosarcoma samples compared with normal osteoblastic
cells. Knockdown of EBF2 led to stunted abrogation of OPG levels and increased
sensitivity to tumor necrosis factor-related apoptosis-inducing ligand
(TRAIL)-induced apoptosis. CONCLUSIONS: These findings suggest that EBF2
represents a novel marker of osteosarcoma. EBF2 up-regulation may be one of the
mechanisms involved in the high levels of OPG in osteosarcoma, contributing to
decrease TRAIL-induced apoptosis and leading to TRAIL resistance
Cortactin (CTTN) overexpression in osteosarcoma correlates with advanced stage and reduced survival
The cortactin (CTTN) gene has been found, by transcriptomic
profiling, to be overexpressed in pediatric osteosarcoma. The location of CTTN at
11q13 and the role of cortactin in cytoskeleton restructuring make CTTN of
interest as a potential biomarker for osteosarcoma. MATERIALS AND METHODS:
Osteoblasts were isolated from 20 high-grade osteosarcomas before chemotherapy,
and paired with cell samples from normal tissue, prior to RNA expression analysis
on HG-U133A chips (Affymetrix). Semiquantitative CTTN mRNA expression was
analyzed by real-time PCR. An osteosarcoma tissue microarray (TMA) containing 233
tissue spots from 48 patients was used for an immunohistochemical (IHC) study of
cortactin. RESULTS: Transcriptomic profiling and real-time PCR analysis indicated
increased CTTN expression in osteosarcomas (p = 0.001, Student's T test). TMA IHC
showed cortactin to be present more frequently and in greater abundance in
osteosarcomas than non-tumoral osteoblastic samples (p< 0.006, Mann-Withney
test). Analysis of clinical outcomes indicated that overall survival for patients
with primary tumors positive for cortactin was significantly lower than that for
patients with cortactin negative (or only weakly staining) tumors (p = 0.0278,
Log-rank test). CONCLUSIONS: Our preliminary data support the hypothesis that
over-expression of cortactin, contained in the 11q13 amplicon, is involved in
osteosarcoma carcinogenesis. The potential of cortactin overexpression as a
biomarker for osteosarcoma is consolidated
Conditional expression of HGAL leads to the development of diffuse large B-cell lymphoma in mice
Diffuse large B-cell lymphomas (DLBCLs) are clinically and genetically heterogeneous tumors. Deregulation of diverse biological processes specific to B cells, such as B-cell receptor (BCR) signaling and motility regulation, contribute to lymphomagenesis. Human germinal center associated lymphoma (HGAL) is a B-cell–specific adaptor protein controlling BCR signaling and B lymphocyte motility. In normal B cells, it is expressed in germinal center (GC) B lymphocytes and promptly downregulated upon further differentiation. The majority of DLBCL tumors, primarily GC B-cell types, but also activated types, express HGAL. To investigate the consequences of constitutive expression of HGAL in vivo, we generated mice that conditionally express human HGAL at different stages of hematopoietic development using 3 restricted Cre-mediated approaches to initiate expression of HGAL in hematopoietic stem cells, pro-B cells, or GC B cells. Following immune stimulation, we observed larger GCs in mice in which HGAL expression was initiated in GC B cells. All 3 mouse strains developed DLBCL at a frequency of 12% to 30% starting at age 13 months, leading to shorter survival. Immunohistochemical studies showed that all analyzed tumors were of the GC B-cell type. Exon sequencing revealed mutations reported in human DLBCL. Our data demonstrate that constitutive enforced expression of HGAL leads to DLBCL development
Las metástasis óseas del cáncer
Las metástasis óseas representan un problema clínico devastador en las neoplasias más frecuentes,
especialmente en el mieloma múltiple, mama, próstata, y pulmón. Las consecuencias incluyen dolores refractarios a analgésicos convencionales, osteolisis que conlleva en ocasiones compresión medular, fracturas patológicas, y trastornos metabólicos. Recientes avances en el diagnóstico mediante técnicas de imagen, así como diversas técnicas bioquímicas, han favorecido un certero diagnóstico y seguimiento. El aumento de la supervivencia se ha mejorado mediante una aproximación multimodal en los tratamientos con la combinación de la inhibición de la osteolisis, la cirugía ortopédica profiláctica y la radioterapia. Recientes progresos en la investigación básica han determinado la huella molecular de metástasis de un tumor capaz de predecir su proclividad metastásica. La investigación básica favorecerá un conocimiento de los mecanismos básicos y llevará a elucidar dianas moleculares que favorecerán el desarrollo de fármacos capaces de prevenir,
amortiguar o bloquear el proceso metastático.Bone metastases represent a devastating clinical problem in the most frequent neoplasies, especially in multiple myeloma, tumours breast, prostate and lung. The consequences include pain which is refractory to conventional analgesics, osteolysis often leading to bone-marrow compression and pathological fractures, and metabolic disorders. Recent advances in diagnosis using imaging techniques as well as different biochemical techniques have helped accurate diagnosis and follow-up. The increase in survival has improved through a multimodal approach combining, inhibition of osteolysis, with prophylactic orthopaedic surgery and radiation
therapy. Recent advances in basic research have determined the molecular metastatic that can predict its proclivity to metastasize. Basic research will improve understanding of the basic mechanisms and lead to the clarification of molecular targets that will help in the development of medicines capable of preventing, decreasing or blocking the metastatic process
Unraveling heterogeneous susceptibility and the evolution of breast cancer using a systems biology approach
This is an Open Access article distributed under the terms of the Creative Commons Attribution License.-- et al.[Background]: An essential question in cancer is why individuals with the same disease have different clinical outcomes. Progress toward a more personalized medicine in cancer patients requires taking into account the underlying heterogeneity at different molecular levels. [Results]: Here, we present a model in which there are complex interactions at different cellular and systemic levels that account for the heterogeneity of susceptibility to and evolution of ERBB2-positive breast cancers. Our model is based on our analyses of a cohort of mice that are characterized by heterogeneous susceptibility to ERBB2-positive breast cancers. Our analysis reveals that there are similarities between ERBB2 tumors in humans and those of backcross mice at clinical, genomic, expression, and signaling levels. We also show that mice that have tumors with intrinsically high levels of active AKT and ERK are more resistant to tumor metastasis. Our findings suggest for the first time that a site-specific phosphorylation at the serine 473 residue of AKT1 modifies the capacity for tumors to disseminate. Finally, we present two predictive models that can explain the heterogeneous behavior of the disease in the mouse population when we consider simultaneously certain genetic markers, liver cell signaling and serum biomarkers that are identified before the onset of the disease. [Conclusions]: Considering simultaneously tumor pathophenotypes and several molecular levels, we show the heterogeneous behavior of ERBB2-positive breast cancer in terms of disease progression. This and similar studies should help to better understand disease variability in patient populations.JPL was partially supported by FEDER and MICINN (PLE2009-119), FIS (PI07/0057, PI10/00328, PIE14/00066), the Junta de Castilla y León (SAN673/SA26/08; SAN126/SA66/09, SA078A09, CSI034U13), the “Fundación Eugenio Rodríguez Pascual”, the Fundación Inbiomed (Instituto Oncológico Obra Social de la Caja Guipozcoa-San Sebastian, Kutxa), and the “Fundación Sandra Ibarra de Solidaridad frente al Cáncer”. AC was supported by MICINN (PLE2009-119). SCLL is funded by a JAEdoc Fellowship (CSIC)/FSE. MMSF and ABG are funded by fellowships from the Junta de Castilla y Leon. WR was supported by a Forschungsstipendium of the Deutsche Forschungsgemeinschaft (DFG) [RE 3108/1-1]. TN, BPB and DYL acknowledge support from the US Department of Energy Low-Dose SFA Program at Berkeley Lab [DE-AC02-05CH11231], the National Institutes of Health [RC1NS069177] and the California Breast Cancer Research Program [15IB-0063]. JHM was supported by the National Institutes of Health, a National Cancer Institute grant (R01 CA116481), and the Low-Dose Scientific Focus Area, Office of Biological and Environmental Research, US Department of Energy (DE-AC02-05CH11231).Peer Reviewe
- …